5 hrs ago
New Form of Recombinant Factor IX Requires Less Frequent Injections for Hemophilia B
A modified version of recombinant factor IX allows patients with hemophilia B to undergo less frequent maintenance injections, according to a New England Journal of Medicine study.
7 hrs ago
Alnylam's CEO Presents at The 25th Annual Piper Jaffray Healthcare Conference
Good day, everyone. And we'll get started with the presenting company Alnylam. My name is Ted Tenthoff.
12 hrs ago
The New England Journal of Medicine Publishes Pivotal Data...
The New England Journal of Medicine Publishes Pivotal Data Demonstrating Prophylactic Infusions of ALPROLIX a Effectively Controlled Bleeding in Hemophilia B Patients )--Today Biogen Idec and Swedish Orphan Biovitrum AB announced the publication of detailed results from the pivotal Phase 3 study of ALPROLIXTM, the companies' investigational ... (more)
16 hrs ago
Heartland announces blood drives
From left, Heartland Blood Center driver/historian Gloria Ackerman screens Naperville North High School student Bridget Deely, 16, at a blood drive in 2007.
18 hrs ago
Albany physician group cures gap in cancer business
"They really give us a true cancer center. We can now offer everything, from diagnosis to surgery," says Bob Desjardins , director of operations for Community Care's oncology division.
Tue Dec 03, 2013
Biogen Idec Demonstrates Commitment to Advancing Hemophilia Research and Care at Annual ASH Meeting
Biogen Idec will present new data from its hemophilia clinical development and research programs at the 55th Annual Meeting of the American Society of Hematology , taking place in New Orleans, December 7-10.
Mon Dec 02, 2013
Sobi's partner Biogen Idec receives notification from FDA of PDUFA date extension for ALPROLIX
Swedish Orphan Biovitrum AB's partner Biogen Idec announced today that the U.S. Food and Drug Administration has extended the initial Prescription Drug User Fee Act date for its review of the Biologics License Application for ALPROLIX, the company's investigational long-lasting recombinant factor IX Fc fusion protein candidate for hemophilia B.
Sun Dec 01, 2013
Recent Study: Alnylam Pharmaceuticals, Inc. (ALNY) - Pharmaceuticals...
The company is primarily involved in its Alnylam 5x15 program for developing RNAi based therapeutics targeted against genetically defined diseases.
Thu Nov 28, 2013
Officials: Discuss family health at Thanksgiving
Department of Public Health Genomics Coordinator Beverly Burke said knowing your family health history is "an important way to understand your risk factors and the preventive steps you can take to keep you and your family healthy."
Wed Nov 27, 2013
Aradigm Announces Appointment of Dr. Juergen Froehlich as Chief Medical Officer
Dr. Froehlich has more than 20 years of pharmaceutical industry experience in preclinical, clinical and regulatory activities at Boehringer Ingelheim, , Dr. Froehlich directed the clinical development, submission and approval of Activase for acute ischemic stroke and the early development of Xolair for the treatment of allergic rhinitis and ... (more)
Tue Nov 26, 2013
The News Journal
Thanksgiving talk could dish out a helping of family history
Here's a prescription for a happy, healthy and productive Thanksgiving, courtesy of the nation's top doc: Eat well, but in moderation.
Mon Nov 25, 2013
Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.
The New England journal of medicine , Vol. 357, No. 6. , pp. 535-544, doi:10.1056/nejmoa067659 BACKGROUND: Effective ways to prevent arthropathy in severe hemophilia are unknown.
Fri Nov 22, 2013
Nike Doernbecher Freestyle X collection goes on sale Saturday
The Nike Doernbecher Freestyle X collection - seven shoes and clothing designed by patients treated at the Portland children's hospital with the help of Nike employees - will be available for purchase Saturday at Nike Portland.
Columbia/Boone County Department of Public Health & Human Services...
The Columbia/Boone County Department of Public Health and Human Services along with Rain, Trail to the Cure, SHAPE, and MU Bond Life Sciences invite the public to attend A Boy, A Girl, and A Virus, Thursday, December 5, 2013 at 6 p.m. The program features Shawn, a hemophiliac who contracted HIV after receiving HIV positive blood during a blood ... (more)
Has A Buying Opportunity In Baxter International Occurred?
I have been following Baxter International for some time now. I was very impressed with the dividend growth over the previous years.
Wed Nov 20, 2013
The Desert Sun
AIDS no longer the fatal condition of 'Buyers Club'
In the 1980s, an AIDS patient would have wondered -- how much time do I have? Today, a patient can live a full, active life and even dare to hope -- will I someday see a cure? The new film "Dallas Buyers Club" offers a moving contrast between the eras.
Researchers at St. Jude Children's Research Hospital Discuss Findings in Gene Therapy
New developments in vector design have fostered improved expression as well as enhanced safety, particularly of integrating retroviral vectors."
Sangamo BioSciences Announces Seven Data Presentations At The 2013...
Sangamo BioSciences, Inc. announced that seven abstracts have been accepted for presentation at the 55 annual meeting of the American Society of Hematology , which will be held December 7-10, 2013, in New Orleans, LA.
The China Post
Gene tests on dogs boost hopes for new treatment for hemophilia
Scientists on Tuesday said they had treated hemophilia in dogs by fixing a flawed gene, marking a step forward towards treating the condition in humans, too.